I-Mab IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| I-Mab | IMAB - NASDAQ |
$12.00-$15.00 | $14.00 | $14.75 | 7.4 million ADSs | 1/17/2020 |
| Jefferies, CICC | ||||||
Co-Manager(s): China Renaissance, Huatai Securities (USA) | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-10-29 Terms Added 2020-01-03 | ||||||
I-Mab Quote & Chart - Click for current quote - IMAB
IPO Boutique aggregates information on public companies and private companies, such as "IMAB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About I-Mab (adapted from I-Mab prospectus):
They are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "IMAB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.